A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Systemic Blockade of ACVR2B Ligands Attenuates Muscle Wasting in Ischemic Heart Failure Without Compromising Cardiac Function (2020)

Szabó, Z., Vainio, L., Lin, R., Swan, J., Hulmi, J. J., Rahtu-Korpela, L., Serpi, R., Laitinen, M., Pasternack, A., Ritvos, O., Kerkelä, R., & Magga, J. (2020). Systemic Blockade of ACVR2B Ligands Attenuates Muscle Wasting in Ischemic Heart Failure Without Compromising Cardiac Function. FASEB Journal, 34(8), 9911-9924. https://doi.org/10.1096/fj.201903074RR

JYU-tekijät tai -toimittajat

Hulmi, Juha

Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajat: Szabó, Zoltán; Vainio, Laura; Lin, Ruizhu; Swan, Julia; Hulmi, Juha J.; Rahtu-Korpela, Lea; Serpi, Raisa; Laitinen, Mika; Pasternack, Arja; Ritvos, Olli; et al.

Lehti tai sarja: FASEB Journal

ISSN: 0892-6638

eISSN: 1530-6860

Julkaisuvuosi: 2020

Volyymi: 34

Lehden numero: 8

Artikkelin sivunumerot: 9911-9924

Kustantaja: John Wiley & Sons; Federation of American Societies for Experimental Biology

Julkaisumaa: Yhdysvallat (USA)

Julkaisun kieli: englanti

DOI: https://doi.org/10.1096/fj.201903074RR

Julkaisun avoin saatavuus: Avoimesti saatavilla

Julkaisukanavan avoin saatavuus: Osittain avoin julkaisukanava

Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/69359

Tiivistelmä

Signaling through activin receptors regulates skeletal muscle mass and activin receptor 2B (ACVR2B) ligands are also suggested to participate in myocardial infarction (MI) pathology in the heart. In this study, we determined the effect of systemic blockade of ACVR2B ligands on cardiac function in experimental MI, and defined its efficacy to revert muscle wasting in ischemic heart failure (HF). Mice were treated with soluble ACVR2B decoy receptor (ACVR2B-Fc) to study its effect on post-MI cardiac remodeling and on later HF. Cardiac function was determined with echocardiography, and myocardium analyzed with histological and biochemical methods for hypertrophy and fibrosis. Pharmacological blockade of ACVR2B ligands did not rescue the heart from ischemic injury or alleviate post-MI remodeling and ischemic HF. Collectively, ACVR2B-Fc did not affect cardiomyocyte hypertrophy, fibrosis, angiogenesis, nor factors associated with cardiac regeneration except modification of certain genes involved in metabolism or cell growth/survival. ACVR2B-Fc, however, was able to reduce skeletal muscle wasting in chronic ischemic HF, accompanied by reduced LC3II as a marker of autophagy and increased mTOR signaling and Cited4 expression as markers of physiological hypertrophy in quadriceps muscle. Our results ascertain pharmacological blockade of ACVR2B ligands as a possible therapy for skeletal muscle wasting in ischemic HF. Pharmacological blockade of ACVR2B ligands preserved myofiber size in ischemic HF, but did not compromise cardiac function nor exacerbate cardiac remodeling after ischemic injury.

YSO-asiasanat: sydäninfarkti; sydänlihassolut; soluviestintä

Vapaat asiasanat: activins; growth differentiation factors; myocardial infarction

Tieteenalat: